4 results
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
To evaluate whether dGEMRIC is suitable as outcome measure to detect changes over time, and also between intervention groups in patients with OA of the knee.
Primary Objective During Double-Blind Period:To compare the efficacy of BMS-945429 SC versus placebo on a background of methotrexate as assessed by ACR20 response rates at 12 weeks.Secondary Objectives During Double-Blind Period:1) To assess…
To assess whether there is (cost) effectiveness over a period of 1 year of additive intra-articular injections with a high molecular HA derivate in patients with OA of the knee.